Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPN-801
- Development stage
- Unknown
- Lead developer
- Epizon Pharma
- Modality
- Small Molecules
01
Overview
EPN-801 is a small molecule therapeutic candidate being developed by Epizon Pharma for the treatment of vascular calcification. The drug's mechanism of action involves the modulation of the vitamin K redox cycle, a biological pathway essential for the carboxylation and activation of vitamin K-dependent proteins, such as Matrix Gla Protein (MGP), which serve as potent inhibitors of vascular mineralization. By targeting this cycle, EPN-801 aims to prevent or reduce the pathological deposition of calcium in the arterial walls, a condition frequently observed in patients with chronic kidney disease and advanced cardiovascular disease. EPN-801 is currently in Phase 1 clinical development.
Beyond the preview
Go deeper on EPN-801.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPN-801.